Bioventus Inc. – NASDAQ:BVS
Bioventus stock price today
$7.32
-3.29
-31.07%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Bioventus stock price monthly change
+62.14%
month
Bioventus stock price quarterly change
+62.14%
quarter
Bioventus stock price yearly change
+99.25%
year
Bioventus key metrics
Market Cap | 684.40M |
Enterprise value | 454.68M |
P/E | -0.4 |
EV/Sales | 0.84 |
EV/EBITDA | -4.04 |
Price/Sales | 0.12 |
Price/Book | 0.21 |
PEG ratio | N/A |
EPS | -0.34 |
Revenue | 522.74M |
EBITDA | 74.39M |
Income | -21.65M |
Revenue Q/Q | 8.73% |
Revenue Y/Y | 0.08% |
Profit margin | -28.9% |
Oper. margin | -6.99% |
Gross margin | 65.78% |
EBIT margin | -6.99% |
EBITDA margin | 14.23% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioventus stock price history
Bioventus stock forecast
Bioventus financial statements
| Jul 2023 | 137.06M | -3.68M | -2.69% |
|---|---|---|---|
| Sep 2023 | 120.79M | -7.30M | -6.05% |
| Dec 2023 | 135.42M | -6.09M | -4.5% |
| Mar 2024 | 129.45M | -4.57M | -3.53% |
| Mar 2024 | 129.45M | -4.57M | -3.53% |
|---|---|---|---|
| Sep 2025 | 139.75M | 4.39M | 3.15% |
| Dec 2025 | 154.15M | 11.02M | 7.15% |
| Dec 2025 | 153.95M | 11.24M | 7.31% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-07 | 0.06 | 0.05 |
|---|
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2019 | 0.84% |
|---|---|
| 2020 | 1.82% |
| 2021 | 0.04% |
| 2022 | |
| 2023 |
| Jul 2023 | 836962000 | 603.62M | 72.12% |
|---|---|---|---|
| Sep 2023 | 811104000 | 584.64M | 72.08% |
| Dec 2023 | 810910000 | 589.79M | 72.73% |
| Mar 2024 | 794238000 | 576.80M | 72.62% |
| Jul 2023 | 10.79M | 33.5M | -62.24M |
|---|---|---|---|
| Sep 2023 | -8.31M | -2.03M | 8.22M |
| Dec 2023 | 10.37M | -591K | -14K |
| Mar 2024 | -7.18M | -1M | -3.06M |
Bioventus alternative data
| Aug 2023 | 1,040 |
|---|---|
| Sep 2023 | 950 |
| Oct 2023 | 950 |
| Nov 2023 | 950 |
| Dec 2023 | 970 |
| Jan 2024 | 970 |
| Feb 2024 | 970 |
| Mar 2024 | 970 |
| Apr 2024 | 970 |
| May 2024 | 970 |
| Jun 2024 | 995 |
| Jul 2024 | 995 |
Bioventus other data
5.91%
-45.20%
of BVS is owned by hedge funds
40
-43
3.62M
-27.89M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 9883 |
| Apr 2024 | 0 | 8379 |
| Jun 2024 | 0 | 51502 |
| Aug 2024 | 105500 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SINGLETON MARK LEONARD officer: SVP & CFO | Class A Common Stock | 31,000 | N/A | N/A | ||
Option | SINGLETON MARK LEONARD officer: SVP & CFO | Restricted Stock Units | 31,000 | N/A | N/A | ||
Option | CHURCH KATRINA J officer: SVP & Chief Compliance.. | Class A Common Stock | 8,600 | N/A | N/A | ||
Option | CHURCH KATRINA J officer: SVP & Chief Compliance.. | Restricted Stock Units | 8,600 | N/A | N/A | ||
Option | D'ADAMIO ANTHONY officer: SVP & Ge.. | Class A Common Stock | 19,850 | N/A | N/A | ||
Option | D'ADAMIO ANTHONY officer: SVP & Ge.. | Restricted Stock Units | 19,850 | N/A | N/A | ||
Purchase | BARTHOLDSON JOHN A. director, 10 percent owner: | Class A Common Stock | 25,500 | $8.55 | $217,974 | ||
Purchase | BARTHOLDSON JOHN A. director, 10 percent owner: | Class A Common Stock | 80,000 | $8.55 | $683,760 | ||
Sale | SINGLETON MARK LEONARD officer: SVP & CFO | Class A Common Stock | 9,219 | $5.57 | $51,350 | ||
Sale | D'ADAMIO ANTHONY officer: SVP & Ge.. | Class A Common Stock | 5,904 | $5.57 | $32,885 |
| Quarter | Transcript |
|---|---|
| Q1 2024 7 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 12 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 12 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 12 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Kenneth M. Reali (1966) Chief Executive Officer & Director | $1,310,000 |
| Mr. John Ernest Nosenzo (1958) Senior Vice President & Chief Commercial Officer | $907,280 |
Ms. Alessandraa Pavesio (1967) Senior Vice President & Chief Science Officer | $634,950 |
| Mr. Anthony D'Adamio (1961) Senior Vice President, Gen. Counsel & Corporation Sec. | $618,290 |
| Mr. Gregory O. Anglum (1971) Senior Vice President, Chief Financial Officer & Principal Accounting Officer | $584,700 |
Bioventus Stock: Improving Outlook Keeps It Interesting
Bioventus: Return Of The King
Avanos: TriVisc Offering Appealing, Strong Growth Across Rest Of Product Portfolio, Revise To Buy
Bioventus: Reiterating Buy Thesis Following Q2 Earnings
Bioventus: Strong Value Gap, Insulated Via Leading Market Share
-
What's the price of Bioventus stock today?
One share of Bioventus stock can currently be purchased for approximately $7.32.
-
When is Bioventus's next earnings date?
Unfortunately, Bioventus's (BVS) next earnings date is currently unknown.
-
Does Bioventus pay dividends?
No, Bioventus does not pay dividends.
-
How much money does Bioventus make?
Bioventus has a market capitalization of 684.40M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 0.04% to 512.35M US dollars. Bioventus made a loss 156.23M US dollars in net income (profit) last year or $0.05 on an earnings per share basis.
-
What is Bioventus's stock symbol?
Bioventus Inc. is traded on the NASDAQ under the ticker symbol "BVS".
-
What is Bioventus's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Bioventus?
Shares of Bioventus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bioventus's key executives?
Bioventus's management team includes the following people:
- Mr. Kenneth M. Reali Chief Executive Officer & Director(age: 59, pay: $1,310,000)
- Mr. John Ernest Nosenzo Senior Vice President & Chief Commercial Officer(age: 67, pay: $907,280)
- Ms. Alessandraa Pavesio Senior Vice President & Chief Science Officer(age: 58, pay: $634,950)
- Mr. Anthony D'Adamio Senior Vice President, Gen. Counsel & Corporation Sec.(age: 64, pay: $618,290)
- Mr. Gregory O. Anglum Senior Vice President, Chief Financial Officer & Principal Accounting Officer(age: 54, pay: $584,700)
-
How many employees does Bioventus have?
As Jul 2024, Bioventus employs 995 workers, which is 3% more then previous quarter.
-
When Bioventus went public?
Bioventus Inc. is publicly traded company for more then 4 years since IPO on 11 Feb 2021.
-
What is Bioventus's official website?
The official website for Bioventus is bioventus.com.
-
Where are Bioventus's headquarters?
Bioventus is headquartered at 4721 Emperor Boulevard, Durham, NC.
-
How can i contact Bioventus?
Bioventus's mailing address is 4721 Emperor Boulevard, Durham, NC and company can be reached via phone at +91 94746700.
Bioventus company profile:
Bioventus Inc.
bioventus.comExchange:
NASDAQ
Full time employees:
1,030
Industry:
Medical - Devices
Sector:
Healthcare
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
4721 Emperor Boulevard
Durham, NC 27703
Durham, NC 27703
CIK: 0001665988
ISIN: US09075A1088
CUSIP: 09075A108
